Restricted accessEditorialFirst published online 2016-4
Sample pooling as an effective way of simultaneous analysis of new designer drugs together with synthetic cannabinoids in human serum provided by therapy and forensic psychiatric centres
CaiXZhangJShouWZ. Sample reduction strategies in discovery bioanalysis. Bioanalysis2013; 5: 1691–1701.
2.
DresenSKneiselSWeinmannW. Development and validation of a liquid chromatography-tandem mass spectrometry method fort the quantitation of synthetic cannabinoids of the aminoalkylindole type and methanandamide in serum and its application to forensic samples. J Mass Spectrom2011; 46: 163–171.
3.
AmmannJMcLarenJMGerostamoulosD. Detection and quantification of new designer drugs in human blood: part 1 – synthetic cannabinoids. J Anal Toxicol2012; 36: 372–380.
4.
KneiselSAuwärterV. Analysis of 30 synthetic cannabinoids in serum by liquid chromatography-electrospray ionization tandem mass spectrometry after liquid-liquid extraction. J Mass Spectrom2012; 47: 825–835.
5.
WohlfarthAWeinmannWDresenS. LC-MS/MS screening method for designer amphetamines, tryptamines, and piperazines in serum. Anal Bioanal Chem2010; 396: 2403–2414.
6.
AmmannDMcLarenJMGerostamoulosD. Detection and quantification of new designer drugs in human blood: part 2 – designer cathinones. J Anal Toxicol2012; 36: 381–389.
7.
PetersFTSchaeferSStaackRF. Screening for and validated quantification of amphetamines and for amphetamine- and piperazine-derived designer drugs in human blood plasma by gas chromatography/mass spectrometry. J Mass Spectrom2003; 38: 659–676.
8.
DziadoszMWellerJPKlintscharM. Scheduled multiple reaction monitoring algorithm as a way to analyse new designer drugs combined with synthetic cannabinoids in human serum with liquid chromatography-tandem mass spectrometry. J Chromatogr B2013; 929: 84–89.
9.
DziadoszMKlintscharMTeskeJ. Mixed consumption of cannabis and ‘Spice’. Forensic Sci Int2014; 235: e1–2.
10.
TuvSSKrabsethHKarinenR. Prevalence of synthetic cannabinoids in blood samples from Norwegian drivers suspected of impaired driving during a seven weeks period. Accid Anal Prev2014; 62: 26–31.
